[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-community-acquired-pneumonia-scap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-community-acquired-pneumonia-scap":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100616091","epidemiology-and-current-practices-in-severe-community-acquired-pneumonia-100616091",false,"NCT07301099","Epidemiology and Current Practices in Severe Community-Acquired Pneumonia","Epidemiology and Current Practices in Severe Community-Acquired Pneumonia (PLENITUDE)","PLENITUDE","Inclusion Criteria:\n\n* Adults aged 18 years or older are hospitalised with a clinical diagnosis of sCAP according to the American Thoracic Society\u002FInfectious Diseases Society of America (ATS\u002FIDSA) criteria.16\n* Admission to participating hospitals or ICUs during the study period.\n* Provision of informed consent by the patient or legally authorised representative for those centres collecting biological samples. Data-only participants will not be required to sign informed consent.\n\nExclusion Criteria:\n\n* Paediatric population (\\\u003C18 years old)\n* Pneumonia acquired in the hospital setting (i.e., nosocomial or hospital-acquired pneumonia).\n* Insufficient clinical information to confirm the diagnosis of sCAP.\n* Immunosuppression: i.e. Active cancer, hematopoietic cell transplant, solid organ transplant recipients, HIV diagnosed patients regardless of CD4 cell count, chronic immunosuppression with corticosteroids, inborn errors of immunity.","ALL","18 Years",{"count":20,"type":21},2588,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn more about severe community-acquired pneumonia (sCAP) in adults who need hospital or intensive care. This type of pneumonia starts outside the hospital and can quickly become life-threatening. The study aims to understand how people with sCAP are cared for in different parts of the world and how these differences relate to their recovery.\n\n* The main questions this study aims to answer are:\n* What are the characteristics, treatments, and outcomes of adults with sCAP?\n* How closely do hospitals follow international guidelines for diagnosing and treating sCAP?\n* What factors are linked to worse outcomes, such as the need for a ventilator or risk of death?\n\nThis study will not test any new drugs or procedures. Instead, researchers will observe the care that participants already receive as part of their normal treatment. Hospitals in many countries will take part, including centres in Europe, North America, Latin America, Asia, Africa, and Oceania. This global participation will help show how sCAP affects people in different health systems and communities.\n\nParticipants will be adults who arrive at a hospital or intensive care unit with severe pneumonia. Most information will come from medical records, such as symptoms, test results, treatments given, and how participants respond to care. In some hospitals with special laboratory capacity, additional blood or breathing samples may be collected to study how the body fights infection.\n\nNo extra visits are required for routine data-only participants. In sites that collect samples, these will usually be taken at the same time as routine medical care to avoid extra procedures. Researchers will also ask about recovery after hospital discharge at 60 days, 6 months, and 12 months. These follow-ups will help us understand long-term health, complications, and quality of life after sCAP.\n\nBy collecting information from a large number of hospitals around the world, this study hopes to identify patterns that can help improve diagnosis, treatment, and survival for people with severe pneumonia. The findings may also help health care teams and public health leaders update treatment guidelines and strengthen care for future patients.",[25],"Severe Community-acquired Pneumonia (sCAP)",[27,28,29,30],"Pneumonia","Respiratory Tract Infections","Community-Acquired Pneumonia","Respiratory Tract Diseases","NOT_YET_RECRUITING","2026-01-14",{"date":34,"type":35},"2026-01-15","ACTUAL",{"date":37,"type":21},"2026-02-01",{"date":39,"type":21},"2027-08-31",{"name":41,"class":42},"Universidad de la Sabana","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100604674","phase-2-randomized-adaptive-platform-trial-of-pathogen-directed-anti-inflammatory-therapy-in-severe-community-acquired-pneumoniacore-protocal-100604674","NCT07152587","Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)","Randomized, Embedded, Multifactorial, Adaptive Platform Trial of Pathogen-Directed Precision Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)","PANDA-SCAP","Inclusion Criteria:\n\n* Admission to ICU;\n\n  * Age ≥ 18 years;\n\n    * ICU length of stay ≤ 48 hours; ④ Meeting the IDSA\u002FATS diagnostic criteria for SCAP.\n\nExclusion Criteria:\n\n* Confirmed diagnosis of hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP);\n\n  * Expected death within 24 hours;\n\n    * Presence of septic shock prior to randomization; ④ History of allergy or contraindications to corticosteroids (e.g., active gastrointestinal bleeding, severe osteoporosis, uncontrolled hyperglycemia, bone marrow suppression);\n\n      * Active fungal (except Pneumocystis jirovecii), tuberculosis, or hepatitis infection;\n\n        * Receiving ongoing corticosteroid therapy at a dose equivalent to prednisone \\> 1 mg\u002Fkg\u002Fday due to underlying disease; ⑦ Participation in this trial within the past 90 days; ⑧ Refusal to sign informed consent.",{"count":53,"type":21},1500,"INTERVENTIONAL",[56,57],"PHASE2","PHASE3","Severe community-acquired pneumonia (sCAP) has a high mortality rate of 25-50%. Excessive host inflammatory responses contribute to poor outcomes. Corticosteroid therapy may provide benefit; however, the optimal dosage remains unclear, and it is uncertain whether all etiologies (e.g., Pneumocystis jirovecii, adenovirus, influenza) of sCAP can benefit equally.\n\nThis study will first establish a comprehensive trial platform based on a prospective sCAP cohort, embedding a randomized, multifactorial, adaptive platform trial (APT). The response-adaptive design will increase the likelihood of patients being assigned to more effective treatment arms, while Bayesian statistical modeling will dynamically assess the efficacy of interventions, allowing early achievement of study endpoints.\n\nAt the starting stage, two pathogen-specific APTs will be conducted, focusing on adenovirus- and pneumocystis Jirovecii-induced sCAP. Patients admitted to the ICU with confirmed diagnoses of adenovirus or pneumocystis Jirovecii-associated sCAP will be randomized into a control group or one of two corticosteroid dosage groups. The primary endpoint will be 28-day all-cause mortality. Completion of these APTs will provide a theoretical basis for novel anti-inflammatory strategies in sCAP.\n\nMoreover, this platform will serve as an essential research infrastructure for the efficient evaluation of new therapeutic options in the event of emerging or re-emerging respiratory pathogens causing sCAP in the future.",[25],[61,62,63,64],"community-acquired pneumonia","adaptive platform trial","pathogen directed","corticosteroids","2025-08-26",{"date":67,"type":35},"2025-09-03",{"date":69,"type":21},"2025-09-08",{"date":71,"type":21},"2035-12-31",{"name":73,"class":42},"Qingyuan Zhan",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":54,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100591201","appropriateness-of-antibiotic-combination-therapy-for-severe-community-acquired-pneumonia-in-south-korea-100591201","NCT06977347","Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea","Verification of Anti-pseudomonal Antibiotic Combination Therapy in Severe Community-acquired Pneumonia in South Korea: A Randomized-controlled Study","ACTSCAP","* Inclusion Criteria:\n\n  * Adult patients aged 19 years or older who visited the emergency department and were hospitalized.\n  * Findings consistent with pneumonia diagnosis, meeting all of the following criteria:\n  * Radiologic evidence of pulmonary infiltration on chest X-ray or chest CT.\n  * At least two or more of the following clinical signs:\n\n    i) Body temperature ≥38°C or \\\u003C36°C ii) White blood cell count ≥11,000\u002FµL or \\\u003C4,000\u002FµL iii) Presence of purulent sputum or bronchial secretions\n  * Within 24 hours of admission, the patient meets one major criterion or three minor criteria according to ATS\u002FIDSA classification:\n\n    * Major criteria:\n\n      i) Invasive mechanical ventilation ii) Use of vasopressors (vasopressor-dependent septic shock)\n    * Minor criteria:\n\n      i) Respiratory rate ≥30 breaths\u002Fmin ii) PaO2\u002FFiO2 ≤ 250 iii) Multilobar infiltrates iv) Confusion or disorientation v) BUN ≥20 mg\u002FdL vi) WBC \\\u003C4,000\u002Fmm³ vii) Platelet count \\\u003C100,000\u002Fmm³ viii) Hypothermia (temperature \\\u003C36°C) ix) Hypotension requiring aggressive fluid resuscitation\n* Exclusion Criteria:\n\n  * Transferred from another hospital after \\>48 hours of hospitalization\n  * Died within 72 hours of hospital admission\n  * Transferred to another hospital within 14 days of admission\n  * Pneumonia occurring after \\>48 hours of mechanical ventilation, including home ventilators\n  * Detection of influenza or SARS-CoV-2 virus within 7 days of hospitalization\n  * Identified non-pneumonia infection requiring antibiotics within 72 hours of admission\n  * Detection of piperacillin\u002Ftazobactam-resistant Enterobacterales, Pseudomonas spp., or Acinetobacter spp. in respiratory or blood cultures within the past 90 days\n  * Antibiotic-related adverse events observed within 72 hours of assigned treatment, requiring discontinuation or change of antibiotics","19 Years",{"count":84,"type":21},100,[86],"NA","This study aims to provide high-level evidence for appropriate empirical antibiotic use tailored to the clinical reality in Korea by conducting a randomized controlled trial comparing monotherapy with piperacillin\u002Ftazobactam and combination therapy with piperacillin\u002Ftazobactam plus a fluoroquinolone in patients with severe community-acquired pneumonia.",[25],"2025-05-09",{"date":91,"type":35},"2025-05-18",{"date":93,"type":21},"2025-06-15",{"date":95,"type":21},"2027-02-01",{"name":97,"class":42},"CHOSEOK YOON"]